替吉奧聯合奧沙利鉑治療晚期結直腸癌的臨床觀察_West China Medical Journal

Authors：

 于瑞蓮 , 陳琳

四川省醫學科學院·四川省人民醫院腫瘤科（成都，610072）;

Corresponding?author：

Keywords：

替吉奧膠囊; 奧沙利鉑; 晚期結直腸癌; 毒副作用

DOI：

10.7507/1002-0179.20140091

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的評價替吉奧膠囊聯合奧沙利鉑治療晚期結直腸癌患者的近期療效和不良反應。方法回顧性分析2010年8月－2012年12月64例晚期結直腸癌患者資料，32例采用替吉奧聯合奧沙利鉑（L-OHP）方案化學療法（替吉奧組），32例采用氟尿嘧啶聯合奧沙利鉑（FOLFOX）方案化學療法（氟尿嘧啶組），2周期后評價兩組療效及不良反應。結果替吉奧組和氟尿嘧啶組總有效率分別為50.0%和46.9%，兩組差異無統計學意義（χ²=0.063，P=0.802）；兩組骨髓抑制及胃腸道反應發生率相近，但靜脈炎的發生率替吉奧組明顯低于氟尿嘧啶組（0.0%、9.4%，P＜0.05）。結論替吉奧膠囊聯合奧沙利鉑治療晚期結直腸癌，近期療效較好，不良反應較輕。

Citation： 于瑞蓮, 陳琳. 替吉奧聯合奧沙利鉑治療晚期結直腸癌的臨床觀察. West China Medical Journal, 2014, 29(2): 300-302. doi: 10.7507/1002-0179.20140091 Copy

1.	Chemotherapy of metastatic colorectal cancer[J].Prescrire Int,2010,19(109):219-224.
2.	Cai X,Cao W,Ding H,et al.Analysis of UGT1A1^*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer:results from a multicenter,retrospective study in Shanghai[J].J Cancer Res Clin Oncol,2013,139(9):1579-1589.
3.	楊學寧,吳一龍.實體瘤治療療效評價標準RECIST[J].循證醫學,2004,4(2):85-111.
4.	周際昌.實用腫瘤內科學[M].2版.北京:人民衛生出版社,2005:606.
5.	Shirasaka T,Nakano K,Takechi T,et al.Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats[J].Cancer Res,1993,56(11):2602-2606.
6.	Tatsumi K,Fukushima M,Shirasaka T,et al.Inhibitory effects of pyrimidine,barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts[J].Jpn J Cancer Res,1987,78(8):748-755.
7.	Shirasaka T,Shimamoto Y,Fukushima M.Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats[J].Cancer Res,1993,53(17):4004-4009.
8.	Van den Brande J,Sch?ffski P,Schellens JH,et al.EORTC Early Clinical Studies Group early phase Ⅱ trial of S-1 in patients with advanced or metastatic colorectal cancer[J].Br J Cancer,2003,88(5):648-653.
9.	Zang DY,Lee BH,Park HC,et al.Phase Ⅱ study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J].Ann Oncol,2009,20(5):892-896.
10.	Hong YS,Park YS,Lim HY,et al.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer:a randomised,non-inferiority phase 3 trial[J].Lancet Oncol,2012,13(11):1125-1132.

1. Chemotherapy of metastatic colorectal cancer[J].Prescrire Int,2010,19(109):219-224.
2. Cai X,Cao W,Ding H,et al.Analysis of UGT1A1^*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer:results from a multicenter,retrospective study in Shanghai[J].J Cancer Res Clin Oncol,2013,139(9):1579-1589.
3. 楊學寧,吳一龍.實體瘤治療療效評價標準RECIST[J].循證醫學,2004,4(2):85-111.
4. 周際昌.實用腫瘤內科學[M].2版.北京:人民衛生出版社,2005:606.
5. Shirasaka T,Nakano K,Takechi T,et al.Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats[J].Cancer Res,1993,56(11):2602-2606.
6. Tatsumi K,Fukushima M,Shirasaka T,et al.Inhibitory effects of pyrimidine,barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts[J].Jpn J Cancer Res,1987,78(8):748-755.
7. Shirasaka T,Shimamoto Y,Fukushima M.Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats[J].Cancer Res,1993,53(17):4004-4009.
8. Van den Brande J,Sch?ffski P,Schellens JH,et al.EORTC Early Clinical Studies Group early phase Ⅱ trial of S-1 in patients with advanced or metastatic colorectal cancer[J].Br J Cancer,2003,88(5):648-653.
9. Zang DY,Lee BH,Park HC,et al.Phase Ⅱ study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J].Ann Oncol,2009,20(5):892-896.
10. Hong YS,Park YS,Lim HY,et al.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer:a randomised,non-inferiority phase 3 trial[J].Lancet Oncol,2012,13(11):1125-1132.

Previous Article
腹腔鏡結直腸癌根治術在合并慢性阻塞性肺疾病患者中的可行性研究
Next Article
麝香保心丸治療老年慢性充血性心力衰竭的療效觀察

West China Medical Journal

替吉奧聯合奧沙利鉑治療晚期結直腸癌的臨床觀察

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content